Rubinstein Mark Lawrence 4

What Happened

• Mark Lawrence Rubinstein, Chief Medical Officer of Achieve Life Sciences, was granted a derivative equity award for 180,000 shares on January 28, 2026. The filing reports a price of $0.00 for the award (derivative instrument); this is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-28; Form 4 filed 2026-01-30 (appears to be within the typical two-business-day reporting window).
• Transaction type: Award/Grant (derivative).
• Amount: 180,000 shares (reported as a derivative award) at $0.00.
• Vesting (per footnote): 1/4 of the award vests on the first anniversary of January 28, 2026, then in substantially equal monthly installments over the following 36 months (total ~4-year vesting), subject to continued service.
• Shares/options owned after the transaction: not specified in the information provided.

Context

• This is a compensation equity grant (an option-like derivative per the footnote) that vests over time; it does not reflect an immediate purchase or sale of shares. Such grants are common for executive compensation and provide future potential upside if the company’s stock performs and the award vests/exercised.